Literature DB >> 10639209

Issues Regarding the Use of Heparin Following Streptokinase Therapy.

.   

Abstract

The success of thrombolytic therapy is dependent upon the balance of fibrinolytic activity and procoagulant activity. Streptokinase produces fibrin degradation products that have anticoagulant effects and may potentially protect against reocclusion. However, streptokinase also activates platelets and thrombin, and the prothrombotic effects may be more marked than after administration of recombinant tissue plasminogen activator (rt-PA). Administration of high-dose, delayed subcutaneous heparin after streptokinase and aspirin has been shown to have some benefits and some risks. The benefits and risks of adding intravenous heparin to aspirin and streptokinase have not been clearly defined.

Entities:  

Year:  1995        PMID: 10639209     DOI: 10.1007/bf01063155

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  50 in total

1.  Influence of skinfold thickness on heparin absorption.

Authors:  C Kroon; A de Boer; J M Kroon; H C Schoemaker; F J van den Meer; A F Cohen; H C Schoenmaker
Journal:  Lancet       Date:  1991-04-20       Impact factor: 79.321

2.  Increased thrombin activity during thrombolysis.

Authors:  R Seitz; H Blanke; G Prätorius; B E Strauer; R Egbring
Journal:  Thromb Haemost       Date:  1988-06-16       Impact factor: 5.249

3.  Heparin kinetics in venous thrombosis and pulmonary embolism.

Authors:  J Hirsh; W G van Aken; A S Gallus; C T Dollery; J F Cade; W L Yung
Journal:  Circulation       Date:  1976-04       Impact factor: 29.690

4.  Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intense fibrinolysis.

Authors:  P R Eisenberg; L A Sherman; A S Jaffe
Journal:  J Am Coll Cardiol       Date:  1987-09       Impact factor: 24.094

5.  The mode of action of heparin in plasma.

Authors:  S Béguin; T Lindhout; H C Hemker
Journal:  Thromb Haemost       Date:  1988-12-22       Impact factor: 5.249

6.  Role of heparin after intravenous thrombolytic therapy for acute myocardial infarction.

Authors:  K Kaplan; R Davison; M Parker; B Mayberry; P Feiereisel; M Salinger
Journal:  Am J Cardiol       Date:  1987-02-01       Impact factor: 2.778

7.  Failure of fixed dose intravenous heparin to suppress increases in thrombin activity after coronary thrombolysis with streptokinase.

Authors:  M Galvani; D R Abendschein; D Ferrini; F Ottani; F Rusticali; P R Eisenberg
Journal:  J Am Coll Cardiol       Date:  1994-11-15       Impact factor: 24.094

8.  Coronary angioscopy in patients with unstable angina pectoris.

Authors:  C T Sherman; F Litvack; W Grundfest; M Lee; A Hickey; A Chaux; R Kass; C Blanche; J Matloff; L Morgenstern
Journal:  N Engl J Med       Date:  1986-10-09       Impact factor: 91.245

9.  GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico.

Authors: 
Journal:  Lancet       Date:  1990-07-14       Impact factor: 79.321

10.  Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma.

Authors:  D M Tollefsen; D W Majerus; M K Blank
Journal:  J Biol Chem       Date:  1982-03-10       Impact factor: 5.157

View more
  2 in total

1.  The TIMI 9b and GUSTO IIb Trials and the "Thrombin Hypothesis"

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

2.  Coronary Artery Patency and Survival in Clinical Trials.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.